(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 1,785.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Ars Pharmaceuticals's revenue in 2024 is $30,000.On average, 3 Wall Street analysts forecast SPRY's revenue for 2024 to be $534,908,114, with the lowest SPRY revenue forecast at $258,624,165, and the highest SPRY revenue forecast at $772,012,432. On average, 3 Wall Street analysts forecast SPRY's revenue for 2025 to be $8,246,347,294, with the lowest SPRY revenue forecast at $5,342,326,029, and the highest SPRY revenue forecast at $13,220,712,898.
In 2026, SPRY is forecast to generate $20,451,091,831 in revenue, with the lowest revenue forecast at $16,154,360,140 and the highest revenue forecast at $24,747,823,523.